acetyl-L-carnitine hydrochloride

DIETARY_SUPPLEMENT2 trials

Sponsors

SWOG Cancer Research Network, Gynecologic Oncology Group

Conditions

Breast CancerChemotherapeutic Agent ToxicityFatigueMalignant Ovarian Mixed Epithelial TumorNeuropathyNeurotoxicityNeurotoxicity SyndromeOvarian Brenner Tumor

Phase 3

S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, II, or IIIA Breast Cancer Undergoing Chemo

CompletedNCT00775645

SWOG Cancer Research NetworkBreast Cancer, Chemotherapeutic Agent Toxicity, Fatigue +2

Start: 2009-09-30End: 2013-06-30Updated: 2017-08-14

Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy

WithdrawnNCT01492920

Gynecologic Oncology GroupFatigue, Malignant Ovarian Mixed Epithelial Tumor, Neuropathy +10

Start: 2012-04-30Updated: 2014-12-31

Related Papers

Two-year trends of taxane-induced neuropathy in women enrolled in a randomized trial of acetyl-l-carnitine (SWOG S0715).

Journal of Clinical Oncology2017-05-205 citations